Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAlejandro BerkovitsASAndrew SpencerFLFei Li

Discussion

Loading...

Member takes

Overview

Phase 3 trial shows pharmacokinetics and clinical outcomes with subcutaneous isatuximab in multiple myeloma, suggesting weight influences efficacy and safety.

Key Points

  • To assess the effects of body weight on pharmacokinetics and clinical outcomes of isatuximab in relapsed/refractory multiple myeloma.
  • International phase 3 trial comparing isatuximab subcutaneous vs intravenous administration.
  • Patients with relapsed/refractory multiple myeloma were randomized to either treatment arm.
  • An analysis of outcomes was stratified by body weight groups with treatment-related adverse events monitored.
  • Isatuximab showed comparable overall response rates across different body weight groups.
  • Grade ≥3 treatment-emergent adverse events decreased with increasing body weight.
  • Neutropenia rates were higher in the ≤50 kg group but did not lead to increased complications.

Cite This Study

Berkovits et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de29https://doi.org/10.1182/blood-2025-5812
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study2025 · 1 citations
  2. 2Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.2026
  3. 3Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study2025
  4. 4Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.2026
  5. 5Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.2026